Skip to main navigation Skip to search Skip to main content

Diabetes insipidus as a complication of Wegener's granulomatosis and its treatment with biologic agents

  • Joanna Rosalind Cunnington
  • , Ramesh Jois
  • , Ivan Zammit
  • , David Scott
  • , John Isaacs

Research output: Contribution to journalArticle

Abstract

Wegener's granulomatosis of the pituitary gland resulting in diabetes insipidus is a rare complication of the disease. Standard treatment for Wegener's granulomatosis involves a combination of prednisolone and cylophosphamide, however biologic agents are now being used in refractory cases. We report three cases of patients with diabetes insipidus as a complication of Wegener's granulomatosis who were treated with biologic agents. All three cases showed clinical response to treatment with biologic agents including rituximab and alemtuzumab and two cases demonstrated improvement in pituitary gland abnormalities by MRI. Clinicians should be aware that diabetes insipidus can present as a complication of Wegener's granulomatosis and that biologic therapies may be effective in refractory cases.
Original languageEnglish
Article number346136
JournalInternational Journal of Rheumatology
Volume2009
DOIs
Publication statusPublished - 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Cite this